Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Camrelizumab Combined With Concurrent Chemoradiotherapy for FIGO IB2-IIIB Cervical Cancer: A Single-center, Single-arm, Open-phase II Clinical Study

NCT05311566 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT05311566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05311566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Camrelizumab Combined With Concurrent Chemoradiotherapy for FIGO IB2-IIIB Cervical Cancer: A Single-center, Single-arm, Open-phase II Clinical Study
Lead sponsor
Lei Li
Phase
Phase 2
Overall status
Unknown status
Start date
March 27, 2022
Completion date
March 27, 2026
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse events, anti-programmed cell death receptor 1, cervical carcinoma, chemoradiotherapy, early stage cervical cancer, immune checkpoint inhibitor, immunotherapy, locally advanced cervical cancer, survival outcomes